Boston Scientific Corp.
What to Expect from St. Jude Medical’s Earnings in 2Q16
In 1Q16, St. Jude Medical exceeded analysts’ EPS (earnings per share) estimate of $0.89 as well as the revenue estimate of ~$1.4 billion.
Weighing in with Boston Scientific’s 4Q15 Revenues
Boston Scientific reported its 4Q15 earnings on February 4 and registered adjusted EPS of $0.26 in 4Q15, which represents 18% YoY growth.
A Look at Boston Scientific’s Valuation Multiples in September
On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.
Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results
On January 29, 2018, Abbott Laboratories (ABT) closed trading at $63.31 per share. The company reported its 52-week high of $64.60 on January 25.
Analysts Raise Target Prices on ABT ahead of Q3 Earnings
Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.
What Really Disrupted Medtronic’s Diabetes Segment Sales in Fiscal 2Q17?
Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 1Q17, ~$0.46 billion came from its Diabetes segment, representing ~6% of the company total.
How Tax Reform Affected Medtronic’s 3Q18 Performance
Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]
Diabetes Management Breakthrough: Medtronic’s MiniMed 670G
On June 7, 2017, Medtronic (MDT) announced the launch of MiniMed 670G—the world’s first HCL (hybrid closed loop) insulin delivery system.
Boston Scientific Expands Its Endoscopy Business with EMcision Acquisition
On March 5, 2018, Boston Scientific (BSX) announced the acquisition of EMcision, which will expand the company’s endoscopy business.
What Led to Edwards Lifesciences’ Stellar Performance in 1Q16?
Edwards Lifesciences (EW) reported ~$697 million in total revenue in 1Q16. Of that, ~$366 million was contributed by the company’s THV (Transcatheter Heart Valve) Therapy segment.
Varian’s Halcyon Treatment System Sees Emerging Market Demand
Halcyon The Halcyon system, Varian Medical Systems’ (VAR) recently launched cancer treatment device, aims to simplify and enhance IMRT (image-guided volumetric intensity modulated radiotherapy). The device has received clearance by the FDA (US Food and Drug Administration). By next year, Varian expects to receive regulatory approvals for the device in China and Japan. For more information […]
ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade
On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close.
Analysts Raise Their Targets on EW ahead of Its Q3 2018 Results
Edwards Lifesciences is set to release its third-quarter earnings results after the market closes on October 23. Let’s see what to expect.
Cooper Companies Reported Mixed 2Q15 Results
Cooper Companies (COO) is a $7.33 billion global medical device company. The company has two business units, CooperVision and CooperSurgical.
Analysts’ Recent Recommendations and Target Price for ABT Stock
On May 2, a Reuters survey noted that of 20 brokerage firms tracking Abbott Laboratories, 16 analysts recommended a “buy” or a “strong buy.”
Will Medtronic Meet Analysts’ Earnings Estimates in Fiscal 1Q18?
For the last several quarters, Medtronic has consistently exceeded analysts’ earnings estimates.
Boston Scientific’s 1Q18 Results: Key Highlights
Yesterday, Boston Scientific released its 1Q18 earnings results. The company registered sales of $2.38 billion.
Abbott Laboratories’ Stock Performance after a Recent Bull Run
On February 16, Abbott Laboratories (ABT) closed trading at $60.17 per share.
Abbott Laboratories’ Stock Price Performance in July
Year-to-date, ABT stock has risen 12.8%. Over the last month, the stock has returned ~4.0%.
How Has Boston Scientific Stock Performed Recently?
Boston Scientific (BSX) was trading at $27.9 on June 29, 2017.
Analysts’ Views on Abbott Laboratories before Q2 2018 Earnings
On July 18, Abbott Laboratories (ABT) is expected to release its earnings results for its fiscal second quarter of 2018.
BSX Stock Regains Momentum after Its Recent Bearish Trend
On February 14, 2018, Boston Scientific stock closed the day at $26.81. The stock was trading near its 50-day moving average of $26.82.
Stryker Declines Buyout Talks with Boston Scientific
On June 13, Stryker (SYK) said in a regulatory filing that it’s not in discussions with Boston Scientific related to its acquisition.
Omega Advisors exits position in Qualcomm
Last month, Qualcomm announced 4Q14 and fiscal 2014 earnings that missed estimates. Its revenue for 4Q14 was $6.69 billion, missing analysts’ expectations by $330 million.
Boston Scientific Stock in the Week Ended September 14
Today, Boston Scientific (BSX) opened at $37.43, down ~0.51% compared to yesterday’s closing price of $37.62.
How BD-Bard Acquisition Will Strengthen International Presence
C.R. Bard (BCR) has grown significantly outside the United States in recent years, driven by its international channel expansion strategy.
Abbott Laboratories’s Valuation before Its 2Q16 Results
After the release of its 1Q16 earnings results on April 20, 2016, Abbott Laboratories (ABT) was trading at a forward PE multiple in the range of 16.4x–19.3x.
Illumina Stock Continues Its Bull Run
Illumina (ILMN) reached a 52-week high of $357.93 per share on August 31.
Examining Abiomed’s Gross Margin Trend
In the second quarter of 2018, Abiomed’s (ABMD) cost of revenue rose YoY (year-over-year) to $29.85 million.
What Can We Expect for Stryker’s Earnings in 2Q16?
In 1Q16, Stryker exceeded analysts’ EPS (earnings per share) estimate of $1.20, as well as the revenue estimate of ~$2.5 billion.
Omega Advisors eliminates position in Boston Scientific
Boston Scientific Corporation is a worldwide developer, manufacturer, and marketer of medical devices that are used in a broad range of interventional medical specialties
Omega Advisors lowers position in Chimera Investment
Chimera Investment invests in residential mortgage loans, residential mortgage-backed securities, real estate-related securities and various other asset classes. Chimera declared a fourth-quarter 2014 cash dividend of $0.09 per common share.
These Developments Impacted Abbott Laboratories the Most in Fiscal 2017
Abbott Laboratories posted a strong earnings results on January 24, surpassing Wall Street estimates and posting earnings at the high end of its guidance.
Here Are the Key Growth Catalysts for Boston Scientific in 2019
In its fourth-quarter earnings press release, Boston Scientific (BSX) reported revenues of $9.82 billion for fiscal 2018.
How Is BSX Overcoming Its Urology and Pelvic Health Headwinds?
On its first-quarter earnings conference call, Boston Scientific said that it expected its Urology and Pelvic Health business’s revenue performance to prove accretive to its revenue in the second half and the whole of 2019. The company expects the resolution of its sterilization issues and its acquisitions of NxThera and Augmenix to drive its Urology and Pelvic Health revenue in 2019.
Boston Scientific or Intuitive Surgical: Which Is a Better Pick?
Boston Scientific (BSX) and Intuitive Surgical (ISRG) are up 17.29% and 6.43%, respectively, YTD (year-to-date). To evaluate which of the two is a better pick in the long run, let’s evaluate the various pros and cons of each.
Boston Scientific or Abbott: Who Will Report More Revenue Growth?
In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) guided for YoY revenue growth of 7%–9%.
What Are Abbott Laboratories’ Key Growth Drivers in 2019?
On its fourth-quarter earnings call, Abbott forecast that its Established Pharmaceuticals segment would grow in the mid- to high single digits YoY in the first quarter.
Boston Scientific’s Free Cash Flow and Tax Rate Guidance for 2018
On its third-quarter earnings conference call, Boston Scientific (BSX) said that it expected its adjusted free cash flow to be $1.9 billion in 2018.
FDA Approves Zimmer Biomet’s ROSA, Stock Up 2.6%
Today, Zimmer Biomet Holdings’ (ZBH) ROSA Knee System received FDA 510(k) clearance for robotically assisted total knee replacement surgeries.
Boston Scientific and Edward Lifesciences Settle Patent Dispute
Today, Boston Scientific (BSX) is trading at $36.76, which is a ~4.11% increase from yesterday’s closing price.
GE’s Healthcare Unit Spin-Off to Enhance Shareholder Wealth
As part of its June 2018 major restructuring plan, General Electric (GE) intends to spin off the Healthcare segment and turn it into a standalone entity.
Do Analysts See Any Upside for Abiomed Stock?
In this year’s second quarter, Abiomed’s (ABMD) net investment income rose YoY (year-over-year) to $1.67 million from $781,000.
Exploring Abiomed’s Latest Performance Trends
In this series, we’ll explore Abiomed’s financials and valuation along with analysts’ views on its stock.
Why Analysts Are Mostly Positive on Boston Scientific Stock
Boston Scientific stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23.
Taking Stock of Edwards Lifesciences’ Performance
A strong operational performance and steady uptick in Edwards Lifesciences’ stock price has kept investors interested in the stock in 2018.
What Analysts Recommend for Hologic Stock
In November 2018, of the total 20 analysts covering Hologic (HOLX), ten analysts have given the stock a “buy” or higher rating, and ten analysts have given it a “hold” rating.
Baxter International: Why Investors Are Interested
Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018.
Johnson & Johnson’s Interventional Solutions Business
JNJ’s Interventional Solutions segment generated third-quarter net revenues of $653.0 million, compared to $553.0 million in the third quarter of 2017.
What Analysts Recommend for Stryker Stock
Of the total 28 analysts covering Stryker (SYK) in October 2018, 19 analysts have given the stock a “buy” or higher rating, and nine analysts have given Stryker a “hold” rating.
Edwards Lifesciences’ Q3 2018 Earnings Estimates
Edwards Lifesciences is expected to register third-quarter adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.
What to Expect of Edwards Lifesciences’ Q3 2018 Sales
Wall Street expects Edwards Lifesciences to register sales of $0.93 billion in the third quarter, representing a YoY (year-over-year) rise of 10.8%.
ABT Stock Registered a 52-Week High in October
On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close.
EW Stock Returned More than the S&P 500’s Gain in 2018
As of September 28, Edwards Lifesciences (EW) has registered a rise of ~52.5% YTD (year-to-date). In the same period, the S&P 500 has risen ~9.2%.
High Valuation Multiples: Is EW Stock an Expensive Bet?
On September 27, Edwards Lifesciences was trading at a forward PE multiple of 33.2x, while its trailing 12-month PE multiple was 39.3x.
Is Abbott Laboratories Trading at a High Valuation in September?
Abbott stock has been gaining momentum recently, and its valuation has improved.
ABT Returns Almost Double the S&P 500’s Year-to-Date Gain
As of September 19, Abbott Laboratories (ABT) has registered a rise of ~17% YTD (year-to-date).
Abbott Laboratories Stock Trades at Its 52-Week High in September
On September 18, Abbott Laboratories (ABT) ended the trading day at $68.41, up ~1.1% from its previous trading day’s closing price.
Cynosure Headwinds Trigger Analyst Downgrades on HOLX Stock
As of September 18, ten of the 19 analysts that cover HOLX stock gave the company a “buy” or “strong buy” recommendation.
Electrophysiology Is Expected to Be a Major Asset for BSX in 2018
In the second quarter of 2018, Boston Scientific’s (BSX) electrophysiology business reported revenue of close to $79 million.
Endoscopy and Urology Businesses Expected to Drive Growth at BSX
In the second quarter, Boston Scientific’s (BSX) endoscopy business reported revenue of close to $442 million, a YoY (year-over-year) rise of ~9%.
What Analysts Expect for Abiomed
Wall Street analysts estimate Abiomed (ABMD) will report 29.9% growth in revenues to ~$771.0 million in 2019 as compared to $593.7 million in 2018.
Do Abiomed’s Valuations Look Attractive?
Abiomed’s (ABMD) revenues rose 36% YoY to ~$180 million in fiscal Q1 2019 compared to $133 million in Q1 2018.
How Analysts View Becton Dickinson in August 2018
On August 29, Becton Dickinson stock closed at $259.35, which represents a ~0.66% growth from its prior day’s close of $257.65.
Haemonetics’s Fiscal Q1 Earnings Surpass Analyst Estimates
Haemonetics reported an 8.7% YoY increase in revenues to $229.3 million during Q1 2019 as compared to revenues of $210.9 million during Q1 2018.
Assessing BSX’s Recently Acquired Cryterion Cryoablation Platform
On July 5, Boston Scientific announced its acquisition of Cryterion Medical, which will add Cryterion’s cryoablation platform to BSX’s atrial fibrillation treatment portfolio.
Electrophysiology Business May Be a Solid Growth Driver for BSX
In the first quarter, Boston Scientific (BSX) reported sales of close to $75 million in its electrophysiology business.
LUX-DX ICM and WATCHMAN LAAC May Prove Solid Drivers for BSX
Boston Scientific (BSX) is preparing to launch the LUX-DX insertable cardiac monitor (or ICM) in both the United States and Europe.
BSX Focuses on Advancing Its Cardiac Rhythm Management Portfolio
Boston Scientific expects the results from its UNTOUCHED trial by 2020.
Spectra WaveWriter Provides Personalized Chronic Pain Therapy
On January 11, Boston Scientific (BSX) announced that the FDA had approved its multitherapy Spectra WaveWriter SCS (spinal cord stimulation) system for providing both sub-perception and paresthesia-based therapy to patients with chronic pain.
Neuromodulation: A Major Growth Driver for Boston Scientific
According to Boston Scientific’s (BSX) estimates, the market opportunity for its neuromodulation portfolio grew ~14% year-over-year in 2017 to ~$2.5 billion.
How BSX Is Set to Benefit from Its nVision Medical Acquisition
On a reported basis, Boston Scientific’s (BSX) urology and pelvic health sales rose 11.8% YoY (year-over-year) to $293 million in Q1 2018, and 9.2% YoY in constant currency.
Boston Scientific Aims to Expand Its Presence in Men’s Health
According to Boston Scientific’s (BSX) estimates, around 110 million people around the world have been diagnosed with BPH (benign prostatic hyperplasia).
Urology and Pelvic Health: Key Growth Drivers for BSX
Boston Scientific (BSX) expects the addressable market for its urology and pelvic health portfolio to grow from $3.5 billion in 2016 to $4.4 billion in 2020.
Pathology, Infection Control: Boston Scientific’s Key Areas?
Boston Scientific (BSX) currently operates the only gastrointestinal (or GI) specialized pathology lab in the United States.
Endoluminal Surgery May Be Opportunity for Boston Scientific
In June, Boston Scientific (BSX) announced the launch of ORISE, its traction solution used in endoluminal surgery.
Boston Scientific: Standard of Care in Pancreaticobiliary Disease
In Q1 2018, Boston Scientific’s endoscopy business reported sales of $418 million, which is a YoY growth of 10.2% on a reported basis.
Boston Scientific: Focused on Category Leadership in Endoscopy
Boston Scientific (BSX) has estimated the market opportunity in pancreaticobiliary disease to be $1.4 billion in 2018 and $1.7 billion by 2021.
Endoscopy: A Major Growth Area for Boston Scientific in 2018
Boston Scientific (BSX) expects the endoscopy market to grow at a CAGR (compound annual growth rate) of 5% from 2017 to 2020.
Analyzing Boston Scientific’s Financial Performance
In Q1 2018, Boston Scientific (BSX) generated sales of $2.4 billion compared to $2.2 billion in Q1 2017.
Analyst Recommendations for Boston Scientific and Peers in June
Of the 24 analysts covering Boston Scientific in June, 19 of them have given the stock a “buy” or higher rating.
Boston Scientific’s Cardiovascular Segment: Q1 2018 Performance
Boston Scientific’s (BSX) Cardiovascular segment’s net sales increased from $851 million in Q1 2017 to $933 million in Q1 2018.
Boston Scientific’s Electrophysiology and Neuromodulation Areas
Worldwide revenues of Boston Scientific’s (BSX) electrophysiology business grew 20% from $64 million in Q1 2017 to $75 million in Q1 2018.
Boston Scientific’s Recent Acquisitions and What They Mean
In April, Boston Scientific (BSX) closed two acquisitions: NxThera and nVision Medical.
How Much Upside Do Analysts See in Baxter Stock?
Of the 17 analysts covering Baxter International in June, ten of them have given the stock a “buy” or higher rating.
MitraClip Drives Growth, Gets Reimbursement Approval in Japan
On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan.
Varian’s HyperArc: Driven by Rising Metastatic Brain Cancer?
Varian Medical Systems’ (VAR) HyperArc is an end-to-end, high-definition, intracranial radiotherapy solution.
BAX May See Slight Rise in Net Profit Margins in Fiscal 2018
In 4Q17, Baxter International (BAX) reported adjusted earnings per share close to $0.64, which represents year-over-year growth of 12.0%.
Analysts’ March 2018 Ratings for Baxter International and Peers
In March, 17 analysts tracked Baxter International. Three gave a “strong buy” rating, seven gave a “buy” rating, and six suggested a “hold.”
Medtronic Launches Its Resolute Onyx 2.0 mm DES
On February 26, 2018, Medtronic (MDT) announced that the FDA has approved the launch of its Resolute Onyx 2.0 mm DES.
What’s Abbott Laboratories’ Current Valuation?
As of March 7, 2018, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 20.8x, while the stock has a PE ratio of 59x.
ABT Gets FDA Approval for World’s Smallest Mechanical Heart Valve
Abbott announced that it received FDA approval for its Masters HP 15-mm rotatable mechanical heart valve, which is the first and only heart valve developed for newborns and infants.
BSX Stock Rises More Than 2% Following EMcision Acquisition
Boston Scientific’s recent stock performance On March 6, 2018, Boston Scientific (BSX) stock closed at $27.41, higher than its 50-day moving average of $27.15 and lower than its 200-day moving average of $27.52. As of March 7, 2018, Boston Scientific’s 52-week high was $29.93 on October 23, 2017, and its 52-week low was $24.02 on March 22, 2017. Factors […]
Wall Street’s Recommendations and Target Prices for BSX
Analysts’ recommendations on Boston Scientific Boston Scientific (BSX) is a leading medical technology company in the United States. The company has been a leading player in minimally invasive therapies for a range of cardiovascular and rhythm management diseases, a space that has become increasingly competitive over the years. Boston Scientific has been expanding in other areas, including endoscopy under its MedSurg […]
Analyzing Boston Scientific’s Business Segments
Boston Scientific (BSX) operates in three business segments that cater to seven different product categories.
Boston Scientific: Analysts’ Ratings in February 2018
In February 2018, 21 of the 26 analysts covering Boston Scientific gave it a “buy” or higher rating, while five analysts gave it a “hold” rating.
Medtronic’s Minimally Invasive Therapies Group in 3Q18
Overview In fiscal 3Q18, Medtronic’s (MDT) MITG (Minimally Invasive Therapies Group) continued to perform poorly, reporting a YoY (year-over-year) decline of ~16% due to the divestiture of the company’s PMR (Patient Monitoring and Recovery) business in fiscal 2Q18. For details, please read Divestiture of a Part of Medtronic’s PMR Business to Cardinal Health. However, on a constant-currency […]
What Drove Medtronic’s Cardiac and Vascular Group in 3Q18
Cardiac and Vascular Group in fiscal 4Q17 Medtronic (MDT) reported total sales of ~$7.4 billion in fiscal 3Q18. Of that total, ~38% (~$2.8 billion) was contributed by Medtronic’s CVG (Cardiac and Vascular Group). CVG sales grew ~10% YoY (year-over-year) and ~7% on a constant-currency basis. US CVG sales grew ~6% YoY, while developed nation CVG sales […]
Analysts’ Latest Recommendations on Boston Scientific Stock
BSX operates in three business segments: MedSurg, Rhythm Management, and Cardiovascular.
BDX’s New Reporting Structure after Bard Acquisition
Becton, Dickinson and Company (BDX) completed the acquisition of Bard on January 29, 2018.